Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy

Cancer Chemotherapy and Pharmacology - 2018
Hitoshi Shibuya1, Susumu Hijioka1, Yasunari Sakamoto2, Tetsuhide Ito3,4, Keijiro Ueda5, Izumi Komoto6, Noritoshi Kobayashi7, Akira Kudo8, Hiroaki Yasuda9, Hayato Miyake9, Junichi Arita10, Sho Kiritani10, Masafumi Ikeda11, Hiroshi Imaoka11, Makoto Ueno12, Satoshi Kobayashi12, Mitsuhiro Furuta13, Yoshikuni Nagashio14, Gou Murohisa15, Taku Aoki16, Shigemi Matsumoto17, Masayo Motoya18, Nobuaki Azemoto19, Jun Itakura20, Shigeru Horiguchi21, Tatsuji Yogi22, Tetsuro Kawagoe23, Youichi Miyaoka24, Fumito Imamura25, Michio Senju26, Hitoshi Arioka27, Kazuo Hara1, Masayuki Imamura6, Takuji Okusaka2
1Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
2Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan
3Neuroendocrine Tumor Center, Fukuoka Sanno Hospital, Fukuoka, Japan
4Internal University of Health and Welfare, Fukuoka, Japan
5Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
6Department of Surgery, Kansai Electric Power Hospital, Osaka, Japan
7Department of Oncology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan
8Department of Hepato-Biliary-Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan
9Division of Gastroenterology and Hepatology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
10Hepato-Biliary and Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
11Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan
12Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Kanagawa, Japan
13Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
14Department of Hepato-Biliary-Pancreatology, National Kyushu Cancer Center, Fukuoka, Japan
15Department of Gastroenterology, Seirei Hamamatsu General Hospital, Shizuoka, Japan
16Second Department of Surgery, Dokkyo Medical University, Tochigi, Japan
17Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
18Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
19Department of Gastroenterology, Shikoku Cancer Center, Matsuyama, Japan
20Department of Gastrointestinal, Breast and Endocrine Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
21Department of Gastroenterology and Hepatology, Okayama University Hospital, Okayama, Japan
22Department of Infectious, Respiratory, and Digestive Medicine, Control and Prevention of Infectious Diseases, Faculty of Medicine, University of the Ryukyu, Okinawa, Japan
23Department of Gastroenterology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
24Department of Endoscopy, Shimane Prefectural Central Hospital, Shimane, Japan
25Hitachi, Ltd., Hitachinaka General Hospital, Ibaraki, Japan
26Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
27Department of Medical Oncology, Yokohama Rosai Hospital, Kanagawa, Japan

Tóm tắt

Từ khóa


Tài liệu tham khảo

Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072

Ito T, Igarashi H, Nakamura K et al (2015) Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 50(1):58–64

Ito T, Sasano H, Tanaka M et al (2010) Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45(2):234–243

Aoki T, Kokudo N, Komoto I et al (2015) Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan. J Gastroenterol 50(7):769–775

Moertel CG, Hanley JA, Johnson LA et al (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189–1194

Frame J, Kelsen D, Kemeny N et al (1988) A phase II trial of streptozotocin and adriamycin in advanced APUD tumors. Am J Clin Oncol 11(4):490–495

Eriksson B, Skogseid B, Lundqvist G et al (1990) Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65(9):1883–1890

Moertel CG, Lefkopoulo M, Lipsitz S et al (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326(8):519–523

Rivera E, Ajani JA (1998) Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21(1):36–38

Cheng PN, Saltz LB (1999) Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86(6):944–948

McCollum AD, Kulke MH, Ryan DP et al (2004) Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 27(5):485–488

Delaunoit T, Ducreux M, Boige V et al (2004) The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 40(4):515–520

Pavel ME, Baum U, Hahn EG et al (2005) Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors. Int J Gastrointest Cancer 35(3):179–185

Turner NC, Strauss SJ, Sarker D et al (2010) Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 102(7):1106–1112

Naidoo J, O’Toole D, Kennedy MJ et al (2012) A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series. Ir J Med Sci 181(2):211–214

Ducreux M, Dahan L, Smith D et al (2014) Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)—a phase II non-randomized trial. Eur J Cancer 50(18):3098–3106

Dilz LM, Denecke T, Steffen IG et al (2015) Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer 51:1253

Krug S, Boch M, Daniel H et al (2015) Streptozocin-based chemotherapy in patients with advanced neuroendocrine neoplasms—predictive and prognostic markers for treatment stratification. PLoS One 10(12):e0143822

Clewemar Antonodimitrakis P, Sundin A, Wassberg C et al (2016) Streptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prognostic factors and toxicity. Neuroendocrinology 103(3–4):345–353

Prakash L, Bhosale P, Cloyd J et al (2017) Role of fluorouracil, doxorubicin, and streptozocin therapy in the preoperative treatment of localized pancreatic neuroendocrine tumors. J Gastrointest Surg 21(1):155–163

Krug S, Boch M, Nimphius W et al (2017) Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy. Pancreatology 17(1):139–145

Krug S, Boch M, Rexin P et al (2017) Impact of therapy sequence with alkylating agents and MGMT status in patients with advanced neuroendocrine tumors. Anticancer Res 37(5):2491–2500

Pavel M, O’Toole D, Costa F et al (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2):172–185

Broder LE, Carter SK (1973) Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 79:108–118

Lamarca A, Elliott E, Barriuso J et al (2016) Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: a lost cause? Cancer Treat Rev 44:26–41

Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523

Raymond E, Dahan L, Raoul J-L et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513

Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117(2):268–275

Kulke MH, Hornick JL, Frauenhoffer C et al (2009) O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15(1):338–345

Thông tin
Thông tin xuất bản

Cancer Chemotherapy and Pharmacology

Thông tin tác giả